Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334710 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer
A Phase 2 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01334710 is a Phase 2 study that was terminated before completion, run by Emory University. The registered enrollment target is 3 participants.
The verdict
NCT01334710, a Phase 2 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of combining a new investigational drug (OSI-906) with a standard drug (sorafenib) on the control of liver cancer (hepatocellular cancer). Sorafenib (brand name Nexavar®) is a drug that is approved for the treatment of advanced liver cancer. It works by stopping the growth of new blood vessels around the tumor. OSI-906 is an investigational agent that works by inhibiting the effects of a growth hormone on the cancer. The safety and efficacy of combining OSI-906 and sorafenib in the treatment of liver cancer risk not known. The current study will confirm the safety of the combination in the first six patients and evaluate the activity of the combination in patients with advanced liver cancer. In addition, the study will aim at collecting blood samples from patients to evaluate the level of OSI-906 in patients receiving the combination of the two drugs. The study also will collect samples of the tumor to evaluate for markers that can predict in which patient the combination is effective.
Interventions
- DRUG Sorafenib and OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334710
The ClinicalTrials.gov registry entry for NCT01334710 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib and OSI-906 is the first listed.
NCT01334710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01334710 about?
NCT01334710 is a clinical study titled "A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer". The purpose of this study is to evaluate the effect of combining a new investigational drug (OSI-906) with a standard drug (sorafenib) on the control of liver cancer (hepatocellular cancer). Sorafenib (brand name Nexavar®) is a drug that is approved for the treatment of advanced liver cancer. It wor...
What is the current status of trial NCT01334710?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2011-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01334710?
The interventions under investigation include: Sorafenib and OSI-906 (DRUG).
Who is sponsoring clinical trial NCT01334710?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.